Podcasts about Baxalta

William A. Lumpkin (Will) is a devoted husband to Layla, a proud father to Ailey, Sage, and Liam, and a purpose-driven leader with a passion for delivering significant impact through high-performing teams. Will serves as Vice President of Sales at Agios Pharmaceuticals in Cambridge, MA, where he leads a team dedicated to providing disease education and access to first and best-in-class solutions for underserved patient populations affected by chronic hemolytic anemia. Prior to Agios, William was Head of New Product Strategy and Business Development at Alexion Pharmaceuticals, Chief of Staff to the Chief Commercial and Global Operations Officer, and the Commercial Integration lead for Alexion into Astra Zeneca rare disease. His innovative solutions earned him Guiding Star and Excellence Awards. With a diverse background spanning leadership across functional disciplines, including finance, sales, marketing, and strategy, at Baxter, Baxalta, Shire, and Takeda, Will has demonstrated his ability to build and lead teams that operate with a sense of urgency in service of others. His professional journey began in finance at Procter & Gamble and includes time as a lecturer at UNC Kenan Flagler School of Business. Will holds an MBA from the University of Chicago Booth School of Business and a Bachelor of Science in Finance from Indiana University, where he excelled as a four-time letterman, senior captain of the Hoosier football team, and President of the Alpha Chapter, Kappa Alpha Psi Fraternity, Inc. Originally from Dayton, Ohio, Will and his family reside in Houston, where he remains actively engaged in community leadership roles, including serving on the Hermann Park Conservatory Board and as a Senior Fellow at the American Leadership Forum. What you'll learn on this episode:  The power of purpose-driven leadership The impact of values on team building and work focus How to connect individual impact to organizational goals The significant role of communication and active listening Strategies for continuous leadership development and growth The importance of authenticity, honesty, and integrity in leadership Additional Resources: William's LinkedIn  Agios Pharmaceuticals' Website >> https://agios.com/  Learn more about PK Deficiency >>  https://www.knowpkdeficiency.com/ Learn more about opportunities to work with Agios and search their open positions below: https://phe.tbe.taleo.net/phe03/ats/careers/v2/searchResults?org=AGIOS&cws=37 

On July 6, Medicare expanded coverage for new Alzheimer's Disease treatments under their Coverage with Evidence Development (CED) policy. Here, we will discuss how CMS, is operationalizing its policy through the recently launched Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease CED Study Registry. Opening Speaker Gary A. Puckrein, PhD President and Chief Executive Officer National Minority Quality Forum Dr. Puckrein is the Founder, President and Chief Executive Officer of the National Minority Quality Forum (NMQF) — formerly the National Minority Health Month Foundation—a not-for-profit organization that he founded in 1998. NMQF addresses the critical need for strengthening preventable illness in minority populations through prevention, early detection, and control of disease complications. In April 2001, the National Minority Health Month Foundation launched National Minority Health Month in response to Healthy People 2010, the national health promotion and disease-prevention initiative. NMQF has received support from a wide variety of organizations, including federal agencies, pharmaceutical companies, payers, and trade associations. With support from the U.S. Department of Health and Human Services and the Robert Wood Johnson Foundation, NMQF undertook the Zip Code Analysis Project, developing a comprehensive database that links vital statistics and other elements—including demographic, environmental, claims, prescription, laboratory, hospital, and clinic data—in a centralized data warehouse, organized around zip codes. The Zip Code Analysis Project has enabled NMQF to develop the Health Assessment Tool, which measures and forecasts health status in small geographic areas, evaluates the impact of specific interventions, monitors changes in health outcomes, and undertakes risk assessments (health-care utilization and its financial implications). NMQF uses the Health Assessment Tool to stratify communities by geographic and health-status referents and to provide the health-disparities movement with a common set of indicators to measure and report on progress toward the elimination of disparities in health care and health status. Dr. Puckrein graduated Phi Beta Kappa from Brown University, where he received his master's degree (1974) and doctorate (1978). Between 1974 and 1992, he taught and lectured at Roger Williams College, Brown University, Connecticut College, and Rutgers University, where he was a tenured member of the faculty. Dr. Puckrein has received many awards and honors, including being named a visiting scholar and fellow at the Smithsonian's National Museum of American History and a visiting fellow at Princeton University. Speaker Amanda Bartelme, BS Executive Director, Policy Eisai, Inc. Amanda Bartelme is the Executive Director, Policy at Eisai, Inc. In her role, she serves as Eisai's lead on all engagement with the Centers for Medicare and Medicaid Services, with a particular focus on ensuring Medicare beneficiaries have appropriate access to treatments. She provides internal support on issues related to access, reimbursement, and drug pricing and represents Eisai on key PhRMA and BIO workgroups focused on drug pricing, access and reimbursement. She joined Eisai in May 2022. Prior to joining Eisai, Amanda held policy roles at GSK, supporting access to vaccines, oncology, respiratory, rheumatology, HIV, and Covid treatments; and at Baxalta where she focused on hemophilia, oncology, and plasma-based therapies. Amanda began her career in health policy and reimbursement at Avalere Health, where she spent over a decade working on access for drugs, devices, and services with a special focus on physician administered drugs, diabetes, biosimilar payment policy, and the 340B program, and the evolving drug pricing and payment landscape.

Baxalta Incorporated v. Genentech, Inc.

Patrice Zagame est médecin, il a fait une immense carrière internationale chez Novartis, Sanofi, Baxalta, Ipsen. Il a été patron de filiale pendant 16 ans sur 4 pays dont la France et en Amérique Latine, il a été membre du COMEX de laboratoires. Aujourd'hui jeune retraité, il a décidé d'entreprendre sur fonds propres : il est le fondateur et CEO d'EOLIAS HEALTH laboratoire d'OTC de produits à base de plantes. J'ai rencontré une personnalité qui étincelle : instinctive et mesurée, un pur mélange de succès et d'humilité. Et bien sûr débordant d'intelligence mêlée à l'expérience. On a parlé de :  son goût très prononcé pour le défi  moments clés à saisir pour devenir CEO  différence entre la carrière et le développement professionnel leadership et d'apprendre à engager 20, 200 ou 2000 personnes responsabilité de gérer le destin professionnel de nombreuses personnes difficile équilibre à tenir entre la réalité des organisations et ses propres valeurs Ceux qui le connaissent savent bien qu'on ne peut pas rester insensible à cette personnalité authentique, qui oscille entre charisme et finesse. Ceux qui ne le connaissent pas vont découvrir comment il est devenu un médecin dans l'industrie, a appris à prendre des risques, à aimer les défis et à vibrer au même rythme que ses organisations. Mais aussi de la complexité de prendre soin de soi et d'assumer sa vulnérabilité. Il s'est confié sans filtre. Je ne peux qu'être impressionnée par son courage.  Notes et références de l'épisode Liens :  Eolias Health : https://eoliashealth.com/  Sur Instagram : https://www.instagram.com/eolias.health/  Le post LinkedIn si vous voulez partager votre retour ou poser vos questions :  https://www.linkedin.com/posts/nathalielahitte_novartis-sanofi-baxalta-activity-7069233381552574464-GUpv?utm_source=share&utm_medium=member_desktop  1. Travaillons ensemble ! THE FARM & CO développe votre visibilité en Pharma en utilisant la force de votre engagement thérapeutique, l'unicité de votre personnalité et la puissance des réseaux sociaux. Construisez une présence alignée avec les valeurs que vous portez. Ghostwriting, création de contenu & bots. 2. Ma newsletter Dans ma newsletter Pharma futurista, 2x/mois je décrypte les évolutions de notre société pour les appliquer au futur de la Pharma. C'est court, 3 min de lecture sur un sujet qui m'a plu. Pour la recevoir, vous pouvez vous abonner sur ce lien : https://nathalielahitte.substack.com/ ou directement sur mon profil LinkedIn. 3. Contactez-moi !  Si le podcast vous plaît, le meilleur moyen de me le dire ou de partager vos avis, c'est sur l'application Apple podcast. Ça m'aide vraiment, n'hésitez pas à partager ! Pour me poser des questions ou suivre mes cheminements, ça se passe sur LinkedIn @nathalie lahitte https://www.linkedin.com/in/nathalielahitte/.

On this episode, I was joined by Niedre Heckman, MPH, PhD, FRAPS, Director of Regulatory Affairs Strategy, CMC, Medical Devices, Combination Products at Takeda.  Niedre discusses: * Common Technical Document * Combination Products Structure for eCTD Submissions * EU vs. US Submission Expectations * Design Controls and Human Factors data placement * Regulatory Roles and Responsibilities in Pharma Niedre Heckman, PhD, MPH, FRAPS is the Director of Regulatory Affairs Strategy, CMC, Medical Devices, Combination Products at Takeda. She's a fellow of Regulatory Affairs Professionals Society (RAPS) (FRAPS), and holds an MPH and PhD in Public Health. Niedre has worked at Takeda, Baxter International Inc., Shire, Baxalta, 3M, and GSK. Niedre has a wide career in Regulatory Affairs, Quality, and Research with focuses in many modalities of medical devices, pharmaceuticals and combination products. Niedre couples her background in RA & QA with her expertise in public health to bring a uniquely patient centric point of view.

On this episode, I was joined by Niedre Heckman, MPH, PhD, FRAPS, Director of Regulatory Affairs Strategy, CMC, Medical Devices, Combination Products at Takeda. Niedre discusses: - Challenges with global regulatory strategies for combination products - Impact of regulatory strategies on patients and product adoption - Becoming an FRAPS, and building wide expertise in QA & RA - Being a great teammate/colleague Niedre Heckman, PhD, MPH, FRAPS is the Director of Regulatory Affairs Strategy, CMC, Medical Devices, Combination Products at Takeda. She's a fellow of Regulatory Affairs Professionals Society (RAPS) (FRAPS), and holds an MPH and PhD in Public Health. Niedre has worked at Takeda, Baxter International Inc., Shire, Baxalta, 3M, and GSK. Niedre has a wide career in Regulatory Affairs, Quality, and Research with focuses in many modalities of medical devices, pharmaceuticals and combination products. Niedre couples her background in RA & QA with her expertise in public health to bring a uniquely patient centric point of view.

Episode Sponsor: This episode's Community Champion Sponsor is Salesforce. Salesforce believes the future of health is connected, do you? Learn more at https://www.salesforce.com/resources/healthcare-life-sciences/business-of-health/?d=7013y000002pgpNAAQ&nc=7013y000002pgpIAAQ&utm_source=direct-search&utm_medium=organic_social&utm_campaign=us_ihls&utm_content=business-of-health-hub_7013y000002pgpNAAQ&utm_term=&soc=us_direct-search (www.salesforce.com/businessofhealth) Hear from Kevin Riley, Salesforce's Chief Customer Officer, on this podcast: https://player.captivate.fm/episode/fefeb2b9-b848-4e52-8289-20a45ba4ae21 (CLICK HERE) Episode Overview:  With deep knowledge and expertise, delivering critically needed and life-saving therapies to patients with rare, ultra-rare, and orphan diseases is our next guest's passion and mission in life.  Jeff Beck, Chief Development Officer at Biocare, joins us to discuss his company's three brands- BioCareSD, a leading national specialty distributor of life-saving therapies, CanyonCareRX, a full-service specialty pharmacy, and LogiCare3PL, a national provider of time and temperature-sensitive pharmaceutical logistics services.  Additionally, Jeff shares why and how the company remaining patient-focused has been the key to its success since 1982.  Join us to discover how Jeff and his team at BioCare are delivering life-saving therapies to patients across our nation. Let's go! Episode Highlights: How Jeff's time with the Harlem Globetrotters prepared him for healthcare Distribution and supply chain logistics during the pandemic  Creating the LogiCare 3PL extension A look into the orphan drugs market Life-changing testimonies from patients BioCare's umbrella services About Our Guest:  As Chief Development Officer at BioCare, Jeff is responsible for setting current and future strategic direction for the company's brands, including BioCareSD, CanyonCareRx and LogiCare3PL. Additionally, Jeff leads the expansion and diversification of BioCare's manufacturer and product portfolio. With a proven ability to build loyal relationships through value-driven selling and rapid problem identification and resolution, Jeff's demonstrated capabilities include strategic planning, budgeting, employee development and cross-functional team collaboration.  Prior to joining BioCare, Jeff served as Vice President of National Accounts a Baxalta, where he was responsible for setting strategic direction and tactical execution.   Links Supporting This Episode: BioCare website: https://biocare-us.com/ (CLICK HERE) Jeff Beck LinkedIn page: https://www.linkedin.com/in/jeff-beck/ (CLICK HERE) BioCare Twitter page: https://twitter.com/BioCareSD (CLICK HERE) Clubhouse handle: @mikebiselli Mike Biselli LinkedIn page: https://www.linkedin.com/in/mikebiselli (CLICK HERE) Mike Biselli Twitter page: https://twitter.com/mikebiselli (CLICK HERE) Visit our website: https://www.passionatepioneers.com/ (CLICK HERE) Subscribe to newsletter: https://forms.gle/PLdcj7ujAGEtunsj6 (CLICK HERE) Guest nomination form: https://docs.google.com/forms/d/e/1FAIpQLScqk_H_a79gCRsBLynkGp7JbdtFRWynTvPVV9ntOdEpExjQIQ/viewform (CLICK HERE)

William A. Lumpkin is Head of New Products Strategy & Business Development for Alexion, Astra Zeneca Rare Disease Business Unit. Will shares how innovation works within the pharmaceutical industry and how marketing and science differs especially in commercialization.More about our guest:William A. Lumpkin is Head of New Products Strategy & Business Development for Alexion, Astra Zeneca Rare Disease Business Unit. His business acumen, enterprise leadership, and passion for cross-functional collaboration helps bring new medicines to people living with rare diseases across the world. Prior to Alexion, he held a diverse set of U.S. and global commercial leadership roles at Takeda, Baxter, Baxalta, Shire, and Procter & Gamble spanning functional disciplines, product lifecycles and therapeutic areas. William is a proud father of three (Ailey, Sage, and Liam), loving husband (Layla), and resilient Indiana University sports fan. He also maintains interests in urban community development initiatives and was on faculty at the University of North Carolina Kenan Flagler School of Business online MBA program. He earned his MBA from the University of Chicago Booth School of Business and B.S. Finance from Indiana University.------------------------------------------------------------Episode Guide:2:03 - What is Innovation3:14 - How people impact innovation6:00 - Seeing the bigger picture in life8:05 - Bigger picture: affecting day-to-day life and effecting innovation and collaboration  8:41 - Earning trust: Top 1 priority10:07 - Stereotyped view of Pharmaceuticals10:52 - Large companies vs smaller companies: Providing real value to people12:21 - What isn't Innovation15:29 - Intersection and divergence of Marketing and Scientists17:14 - Implications of the commercialization cycle19:43 - Experiences that shaped Professional development views22:22 - People: structures, connections, and excitement22:56 - People of Color: finding energy and importance of passion23:49 - Being "me" all day long in the Corporate America26:14  - Advice for future innovators (and the public)--------------------------OUTLAST Consulting offers professional development and strategic advisory services in the areas of innovation and diversity management.

On this episode, I had Marta New PhD MBA. Marta and I talk about how business school changed her perspective, depth vs. the value of information when it comes to decision making, mentors in her career and their influence on her development, her experience starting a new company, her time in venture capital and the due diligence process, lessons during the pandemic and some of the influences that inspire her. Happy Thanksgiving! Marta is the CEO of Radyus Research. Before starting Radyus, Marta was the co-founding Partner at Agent Capital, a life sciences-focused venture capital firm based in Cambridge, MA. While at Agent, Marta participated in multiple deals in oncology, immunology and rare disease areas including Orchard Therapeutics (NASDAQ:ORTX), Precision Biosciences (NASDAQ:DITL), Pliant Therapeutics and Verge Genomics, among others. Prior to Agent Capital, Marta was a Principal investor at Baxalta Ventures, the corporate venture capital arm of Baxalta in Cambridge MA, where she was  on the investment dilligence team and served as a board observer for Gadeta BV (acquired by Kite/Gilead, 2018), Syntimmune (acq. by Alexion, 2018), and Vitesse Biologics (early stage accelerator funded by Baxalta, Mayo Clinic and Velocity Pharmaceutical Development). Marta started her investment career at Baxter Ventures, the corporate venture capital arm of Baxter in Chicago, IL, transitioning from the Global Renal Marketing franchise, where she was the commercial lead for multiple new products for the Chinese and European markets. She joined Baxter from Northwestern University's Innovation and New Ventures Office where she was responsible for licensing negotiations, commercial assessment of patents, and industry alliance management. She received her Ph.D. from the University of Illinois at Chicago in microbiology and immunology and completed her post-doctoral training at Northwestern University. She also received an MBA from Northwestern University Kellogg School of Management in Chicago, IL.

In this episode, Thomas Bertels and John Glasspool discuss the importance of collaboration to build successful, purpose-driven teams. John is the current CEO of Anthos Therapeutics, a clinical-stage biopharmaceutical company, and an MIT advisor and a board member. Prior to Anthos, he served as a senior executive at Baxalta, Baxter, Novartis, and J&J.       In the conversation, John lays out the argument why collaboration is so crucial for biopharma companies and what the benefits of a collaborative culture are,  challenges common perceptions about the downside of collaboration, and provides a framework for how to start building such a culture. 

In this episode, Geeta Vemuri talks to us about her journey into healthcare focused venture capital and applying science to business. She also addresses how the current environment has prompted her team to look into opportunities that are opening up in the form supply chain disruptions and her philosophy that there is no right time to start a company.Geeta is a founder and managing partner at Agent Capital, one of only 4 majority women owned U.S. based Bio Pharma Venture Capital funds, investing in companies that look to treat oncology, immunology, rare diseases, and neurology. Geeta came to the U.S. in 1992 following an invitation to do her post-doc from a national academy of science scientist, but upon arriving, she realized her passion for taking science from the lab and translating it into businesses. She previously held the role of Vice President at Baxalta Ventures along with Vice President of Baxter Ventures. Geeta earned her Ph.D in biochemistry from the Indian Institute of Science and her MBA from Wharton.

Tim Mikhelashvili sits down with Thom Singer for episode 605 of the Making Waves at C-Level Podcast.  Tim lives in New York and was born in the Republic of Georgia. He is a Doctor of Pharmacy with a Post-doctoral fellowship from Rutgers University in Scientific Publications and Medical Education with 15 years of experience in the pharmaceutical industry in headquarters-based and primarily field-based Medical and Medical Science Liaison (MSL) Trainer roles spanning both large, established companies such as AstraZeneca and Sanofi-Aventis early in my career before moving on to small, specialty, rare disease and start-up companies such as Salix and Baxalta, among others.   Adding energy, excitement, and character to help individuals and organizations "stretch themselves and lift others" is his current focus and a business. Dating back to when he was starting his career, Tim has hired and mentored professionals who have gone on to become global, recognized leaders in the pharmaceutical industry and have since then consulted executive management in different start up companies on leading new company culture and organizational change initiatives.   Certified in "Leading Organizations and Change" by the MIT Sloan School of Management, Tim has a solid track record of driving company-wide company culture initiatives as the single representative from the Medical organization. About Tim Mikhelashvili Currently Tim Mikhelashvili coaches both junior and senior level professionals on career development. In addition, he consults exciting start-ups as well as established pharmaceutical and other companies providing solutions to pharma, healthcare, and beyond. Below are some of Tim's services and activities:   Services:   Job interview preparation Resume/CV and cover letter optimization  Company Culture and Organizational Change Management consulting Key Performance Indicators (KPIs) Metrics Customer Relationship Management (CRM) Database Analytics and Optimization Medical Insights Generation Process and Communication for field Medical (MSL) teams Presentation Skills Training and Rehearsal Sessions   Additional Activities:   Writing articles on LinkedIn,  Interviewing Leaders in Pharma and other industries for my Podcast Video Courses and Editorials on YouTube Live / online training webinars   Next Generation Leadership Keynote Speeches   About The ALLOUTCOACH Philosophy Alloutcoach is based on Tim's long-time philosophy, and is now his personal brand in which he inspires people to go "All Out" more often with their work, projects, friends, and relationships over the long term through my "stretch yourself, and lift others" motto, as opposed to an "All In" approach for a short-term episode of performance with a high level of risk. During a time when true dialogue and meaningful relationships have both become a true luxury, Alloutcoach will prioritize to be your personal sounding board, rehearsal partner, mentor, coach, speech editor, writer, speaker, and an important source of energy, excitement, and character.   https://thomsinger.com/podcast/tim-mikhelashvili 

#V3Podcast Episode 8 with Dr. Anne Arvizu and Guest Amy Ravi In this episode, I open the show talking about what’s going on in medical communications and medical affairs with the rise of COVID-19. My aim for this episode is to bring some digital or remote working solutions in Medical Affairs to light. Today, I bring colleague and fellow company owner, Amy Ravi on the show, to discuss creative ways for you to benefit right now. Hopefully the conversation we have sparks some ideas regarding things you can implement now to navigate change over the next few months and beyond. Are you losing staff or ramping up staff? Are you busier than ever or struggling in some way? Every company is different. We discuss virtual technologies and platforms that you can use regardless of your status. Ami Ravi is founder and CEO of Extendmed. We discuss client trends we are seeing, including the needs for consultants and virtual advisory boards. The biggest driver is needing a back-up plan for our functions that was due to take place. Amy says her clients are shifting meetings from in-person to reconstructing it virtually. They also need to gather insights beforehand because it’s harder to stay engaged online for eight hours. Instead, people are creating discussion boards with written content. It’s incredible how people are revamping and repurposing these meetings to make things work. That’s innovation in my opinion!  Next, I ask Amy to explain the essential elements anyone can use today to move advisory boards online. The first and most important step is to address the question of the crucial nature of an advisory board. Don’t be so product-focused – think about offering support to health care professionals and their patients. Virtual advisory boards can take on the tone of ‘overtime’. Think about how to engage with people over a series of months. Other ideas regarding engagements with HCPs and how that may change are discussed in the episode. We agree, the world will change drastically after the COVID-19 outbreak. Companies don’t need to continue getting together for every advisory board. Consultants can be based at home. Both actions will save long term costs and help redefine what’s essential for every business. Links below for both Extendmed and RxER Communications Corp for your convenience. RxER V3 Resources: For a free consultation and for medical affairs consulting, visit: https://rxercommunications.com/ RxER’s newest initiative, Corecentryx, Inc. is a productivity tool that can help us maintain projects and stay energized during this long haul.  As a response to the Coronavirus, Anne Arvizu will be conducting a series of upcoming free livecasts to gather health care professionals and help them combat burnout.  More information will be provided soon at https://annearvizu.com/. For more information about ACMA to become board certified in Medical Affairs visit:  https://training.medicalaffairsspecialist.org/affiliate_page.aspx?unm=anne.aflt.arvizu To listen to other podcasts on the Pharmacy Podcast Nation, our flagship home on the Pharmacy Podcast Network, subscribe on iTunes or visit: http://pharmacypodcast.com/ If you have something to add to the conversation or would like to be interviewed on the show, contact Anne. https://rxercommunications.com/ In this Episode: The most significant demands right now [ 8:15 ] How to move advisory boards online [ 16:30 ] Is it difficult to get in touch with advisors? [ 20:45 ] Are the outcomes different from virtual engagements? [ 23:30 ] Are any product areas taking a hit right now? [ 26:40 ] How will the world change or differ after COVID-19? [ 29:45 ] About Extendmed [ 32:40 ] Quotes: “We should share information in real-time online.” -Amy Ravi       “Defining essential does not mean it has to be labeled COVID-19.” -Amy Ravi “There are essential aspects to continuing our advancement across the board.” -Amy Ravi “Without health, we can’t function.” -Dr. Anne Arvizu “Don’t get bogged down in the how. Find the what and the why and the how will emerge.” -Dr. Anne Arvizu “If you are listening to this episode, you are lucky, and you are blessed.” -Dr. Anne Arvizu “If you are an essential worker, my hat goes off to you, and my prayers go up for you.” -Dr. Anne Arvizu “I’ve seen companies ramp up so quickly without having the bandwidth to do so.” -Dr. Anne Arvizu “We don’t have time for yesterday’s news.” -Dr. Anne Arvizu All Links Mentioned:  Anne’s LinkedIn: https://www.linkedin.com/in/annearvizu/ Anne’s Twitter: https://twitter.com/AnneArvizu Amy’s LinkedIn: https://www.linkedin.com/in/amyravi/ Amy’s Twitter: https://twitter.com/amyravi Extendmed: https://www.extendmed.com/solutions/connecting/ Extendmed on Twitter: https://twitter.com/extendmed Extendmed on LinkedIn: https://www.linkedin.com/company/extendmed/ Rush University: https://www.rush.edu Medscape interview by Abraham Verghese from 3/27/20: https://www.medscape.com/viewarticle/927296?faf=1&src=soc_tw_200331_mscpedt_news_psych_matm Company that hosted HIMSS virtual meeting alternative is 1 Up Health: https://1up.health/virtual-health-conference/vhc20 Human Diagnosis App/Project: https://www.humandx.org/ About Anne: Dr. Anne Arvizu, creator and host of the V3 Medical Affairs Podcast, is founder and CEO of RxER Communications Corp (www.rxercommunications.com). With 22 years of executive leadership experience in the pharma/biotech industry, she has served in key roles such as Head of Global Medical Information, Knowledge Management & Literature Surveillance for Baxter, Baxalta & Shire; Member Executive, PhactMI; International Regional Head & Director of Medical Communications & Medical Information for GSK, LATAM; DIA MASC Program Committee & Track Chair for The Drug Information Association; Podcast Founder & Host for The ACMA (#V3Podcast) (The Accreditation Council For Medical Affairs); Board Member of The American Medical Writers Association (AMWA), and, as an advocate for community health, she serves as Chair, South Florida YMCA Board of Directors in her community. She holds degrees for University of Florida (PharmD), University of the Sciences in Philadelphia, and Villanova University.  Anne currently engages biotech CMOs and VP Level executive clients as an expert consultant for Medical Affairs Capabilities build, renovation, and value-based business expansion. We are your outsourced VP of Medical Affairs. Please like, share and leave a comment. This episode is sponsored by the University of California Irvine, UCI, Master of Science in Pharmacology, learn more: https://sites.uci.edu/mspharmacology/ 

Coronavirus –Productivity & Continued Preparedness in Medical Affairs #V3Podcast Episode 7 with Dr. Anne Arvizu and Guest Dr. Suzanne Soliman In this episode, Anne provides excellent resources and links to use for knowledge base, as a means to keep up with true facts and help you and your loved ones say no to fear and false information. This podcast is meant to help healthcare professionals protect themselves and inform others. Almost every industry in the US and beyond at this point has made a massive shift and Anne shares valuable consulting advice regarding the re-direct toward a new normal in Medical Affairs, Medical Communications, Publications and Medical Information. Any company, especially those working on Coronavirus vaccines or antiviral solutions may contact RxER Communications at support@rxercommunications.com to schedule a free consultation and strategy call with Anne. Focus: The aim of today’s episode today, is providing guidance for the current changes in the Biotech industry. The tone of this planned podcast has shifted dramatically in the last week since taping on March 12.  Every day, and even every hour brings with it significant changes as we track. It’s time to not be caught up in the news, but be educated with the facts and forge our new normal. During the first half, Anne discusses how HCPs (Pharmacists, Physicians, Nurses) are affected and then opens up the second half of the show with a conversation with special guest expert, Dr. Suzanne Soliman, on continued prevention measures to help answer the most common questions we are all receiving right now from the lay public. The aim is to hopefully better equip, protect and prepare the health professional so they can better help and continue to prepare others. Although it is not mentioned in the show, our biggest risk factor right now in the US, is Millennials who continue to go out, travel and not take this seriously. It’s been said the virus rate will depend on them. It’s a time to stay home and distance yourself from other people as much as possible. Anne invited Suzanne Soliman, founder of the Pharmacist Mom’s Group, on the show to discuss preparedness; Suzanne earned her PharmD from the University of Illinois at Chicago College of Pharmacy (UIC-COP) in 2004. She completed a residency in primary care with an emphasis on education at Midwestern University Chicago College of Pharmacy and a teaching fellowship at UIC College of Medicine. Dr. Suzanne Soliman is a board-certified medical affairs specialist (BCMAS). Suzy worked as a clinical pharmacist, a medical science liaison (MSL) and national field team educator prior to becoming an Assistant Dean of Academic Affairs at UIC-COP. She most recently was an Associate Dean at Touro College of Pharmacy New York and an independent pharmacy owner. Currently, she is the Chief Academic Officer for the Accreditation Council for Medical Affairs (ACMA). More Key Points: It’s only been two weeks, but some of the recommended household items are completely gone. Some are being restocked or produced and will be back. There is still time to get some basics prepared. The time to pick up your medications is sooner rather than later. Get your refills NOW. Suzanne also discusses what’s still available and what can still be done. Should we get tested for Coronavirus? We need to keep our healthcare workers healthy, make sure your ER visit is valid. We can get more sick from the emergency room. Sometimes staying home is better than going to the hospital. Call ahead of time so they can have a self-quarantined room ready for you. In the US, your county will provide guidance on where to get tested. Is there a vaccine or other therapy coming out for the virus? There are various companies and treatments on top of the crisis as well as the production of a potential vaccine. Depending on the country that is trying to develop it, there are different methods currently being tested regarding treatment. You may be able to get the virus twice, because there seems to be a mutation. This makes creating a vaccine that much harder. Stay tuned, as Dr. Soliman explains when to keep your kids at home. Please like, share and leave a comment. Other Resources: For a free consultation and for medical affairs consulting, visit: https://rxercommunications.com/ RxER’s newest initiative, Corecentryx, Inc. is a productivity tool that can help us maintain projects and stay energized during this long haul.  As a response to the Coronavirus, Anne Arvizu will be conducting a series of upcoming free livecasts to gather health care professionals and help them combat burnout.  More information will be provided soon at https://annearvizu.com/. For more information about ACMA to become board certified in Medical Affairs visit:  https://training.medicalaffairsspecialist.org/affiliate_page.aspx?unm=anne.aflt.arvizu To listen to other podcasts on the Pharmacy Podcast Nation, our flagship home on the Pharmacy Podcast Network, subscribe on iTunes or visit: http://pharmacypodcast.com/ If you have something to add to the conversation or would like to be interviewed on the show, contact Anne. https://rxercommunications.com/ In this Episode: About Dr. Suzanne Soliman and Pharmacist Moms [ 0:15 ] Supplies that we need [ 3:15 ] Should we get tested? [ 11:15 ] Is there a vaccine coming out? [ 17:00 ] Can you get the same virus twice? [ 20:15 ] When should you keep your kids at home? [ 23:10 ] Quotes: “This is going to get worse before it gets better.” -Dr. Suzanne Soliman “We need to keep our healthcare workers healthy.” -Dr. Suzanne Soliman “Encourage all employees to work remotely if they can.” -Dr. Suzanne Soliman “We see that history repeats itself...don’t get caught up in the news, learn and apply facts” -Dr. Anne Arvizu “Any government has a responsibility to maintain mass hysteria and provide the facts.” -Dr. Anne Arvizu “Knowledge is only power if acted upon.” -Dr. Anne Arvizu Links Mentioned:  Pharmacist Moms: https://www.pharmacistmomsgroup.com Our World in Data: https://ourworldindata.org/coronavirus - *Anne’s top pick for data* World Health Organization: https://www.who.int/ Computer virus: https://www.forbes.com/sites/zakdoffman/2020/03/11/warning-you-must-not-download-this-dangerous-coronavirus-map/#634337113253 For those interested:  https://www.cdc.gov/coronavirus/2019-ncov/about/steps-when-sick.html https://www.cdc.gov/coronavirus/2019-ncov/php/pandemic-preparedness-resources.html https://www.who.int/gpsc/5may/Guide_to_Local_Production.pdf https://www.bloomberg.com/news/articles/2020-01-27/drugmakers-hunt-for-ways-to-halt-virus-that-eludes-travel-curbs https://time.com/5782633/covid-19-drug-remdesivir-china/ For prevention: *Suzanne Soliman’s Article Discussed On This Show*: https://www.pharmacytimes.com/news/pharmacist-moms-recommend-essentials-for-coronavirus-preparedness Alcohol 70% vs 90 or 99% use: https://blog.gotopac.com/2017/05/15/why-is-70-isopropyl-alcohol-ipa-a-better-disinfectant-than-99-isopropanol-and-what-is-ipa-used-for/  Published articles: https://nypost.com/2020/03/03/chinese-doctor-who-worked-with-late-whistleblower-dead-from-coronavirus/ https://nypost.com/2020/02/09/coronavirus-doctor-li-wenliangs-mother-demands-answers-after-his-death/ https://nypost.com/2020/02/06/li-wenliang-chinese-doctor-who-sounded-alarm-on-coronavirus-dead-from-disease-at-34/ About Anne: Dr. Anne Arvizu is founder and CEO of RxER Communications Corp (www.rxercommunications.com). With 22 years of executive leadership experience in the pharma/biotech industry, she has served in key roles such as Head of Global Medical Information, Knowledge Management & Literature Surveillance for Baxter, Baxalta & Shire; Member Executive, PhactMI; International Regional Head & Director of Medical Communications & Medical Information for GSK, LATAM; DIA MASC Program Committee & Track Chair for The Drug Information Association; Podcast Founder & Host for The ACMA (#V3Podcast) (The Accreditation Council For Medical Affairs); Board Member of The American Medical Writers Association (AMWA), and, as an advocate for community health, she serves as Chair, South Florida YMCA Board of Directors in her community. She holds degrees for University of Florida (PharmD), University Of Sciences in Philadelphia, and Villanova University.  Anne currently engages biotech CMOs and VP Level executive clients as an expert consultant for Medical Affairs Capabilities build, renovation, and value-based business expansion. Please like, share and leave a comment.

Open communication and high performing teams don’t just appear out of nowhere. In order to have a team that gels, you need to put in the work to create a space in which all team members know the vision of your company, have clear expectations, and know how to course-correct when things go awry.Eric Foster, a CIO with experience spanning multiple technology firms sat down to speak with Pat and Shelli on his three-part framework for creating high performing teams. Eric also explains why it is so important that you spend time thinking about the culture you want and how to go about creating it. Listen in for tips and book recommendations so you have the tools you need to create an unstoppable team.[00:23] - This week: Eric Foster[01:25] - Individual all-stars or a high performance team: Reflecting on the 2004 US Olympic Basketball team[03:06] - 3-part framework for improving team effectiveness:[04:26] - Clarity[06:00] - Accountability[07:08] - Course correction[09:34] - Integrating external resources[15:16] - Building high-trust environments[21:00] - Creating a strong culture[27:38] - Building trust as a leader[28:32] - Retaining great people[29:32] - The Leadership Cube for aspiring leaders[32:15] - Serving the organization Eric Foster has been a technology executive in a variety of industries, including Distribution, BioPharmaceuticals, Medical Products, Advertising and Financial Services.   He has been CIO for two Fortune 500 companies, Univar and Baxalta, and has served in IT leadership positions at Baxter International and Heller Financial, as well as CTO for Publicis Groupe.  He started his career in consulting at Andersen Consulting (now Accenture). He has a bachelor’s degree in Aeronautical and Astronautical Engineering from the University of Illinois.If you'd like to receive new episodes as they're published, please subscribe to Innovation and the Digital Enterprise Insider in Apple Podcasts, Google Podcasts, Spotify or wherever you get your podcasts. If you enjoyed this episode, please consider leaving a review in Apple Podcasts. It really helps others find the show.This podcast episode was produced by Dante32. 

1. Early predictors of mortality in parkinsonism and Parkinson’s disease: a population-based study 2. [What’s Trending]: Data from the Largest Natural History Study of Stiff Person Syndrome. In the first segment, Dr. Jeffery Ratliff talks with Dr. David Bäckström about his paper on Early predictors of mortality in parkinsonism and Parkinson’s disease. In the second part of the podcast, Dr. Jeffery Ratliff focuses his interview with Marinos Dalakas on Stiff Person Syndrome. DISCLOSURES:Dr. Jeff Ratliff has received speaker honoraria from Teva and US WorldMeds LLC; is the deputy editor for the Neurology Podcast; has been a consultant for UCB Pharmaceuticals, US WorldMeds LLC, Medscape, and Retrophin Inc; and has served on speakers' bureaus for Teva and US WorldMeds LLC. Dr. David C Bäckström holds patents for chemical compounds that may be developed as treatments for premenstrual dysphoric disorder, but has not received any personal compensation for the patents. Dr. David C Bäckström has received Research Support from Swedish Medical Research Council, grant number (K2013- 62X-15224-10-4) and unrestricted grant for Parkinson's disease research and has received foundation and societies research support from Erling Persson Foundation, Umeå University, Västerbotten County Council, King Gustaf V and Queen Victoria Freemason Foundation, Swedish Parkinson Foundation, Kempe Foundation, and Swedish Parkinson’s Disease Association. Dr. Marinos Dalakas serves the CIDP steering committee for Novartis and on DSMB for Baxalta and Octapharma, has received funding or served as a travel speaker honoraria for Merck/Serono, OCTAPHARMA, PFIZER AG. Dr. Marinos Dalakas has served on editorial board including Neurology, editorial board (5 years, not compensated), BMC Neurology (Section Editor, 5 years not compensated), Acta Myologica, editorial board (5 years, not compensated), Acta Neurologica Scandinavica editorial board (5 years, not compensated), and Therapeutic Advances in Neurology (Associate Editor; 4 years, compensated). Dr. Marinos Dalakas consultancies include work with Therapath, Baxter, Octapharma, CSL, Dysimmune Diseases Foundation and he has received research and institutional support from Thomas Jefferson University Neurology department or to Neuroimmunology Unit, University of Athens Medical School for research and education from: Merck-Serono, Genzyme, Novartis, Guillain-Barre/CIDP Foundation, Dysimmune diseases Foundation, CSL, Biogen and Newfactor.

In this discussion with John Glasspool, a recognized thought leader on patient access and an experienced commercial leader who served in senior roles at Baxalta, Baxter, Novartis and Janssen, we explore the implications of the inevitable shift from price to value.

1) A Randomized, Double-Blind, Placebo-Controlled Trial of Coenzyme Q10 in Huntington's Disease 2) What's Trending: Risk assessment in Duchenne dystrophy3) Topic of the Month: Neuromuscular medicineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 10, 2017 issue of Neurology. In the first segment, Dr. Michelle Fullard talks with Dr. Andrew McGarry about his paper on a randomized trial of coenzyme Q10 in Huntington Disease. Dr. Ted Burns talks with Dr. Sindhu Ramchandren about her Neurology: Genetics paper on Duchenne dystrophy for our “What's Trending” feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Gil Wolfe on myasthenia gravis. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. McGarry serves on an advisory board for Teva Pharmaceutical Industries, Ltd.; receives speaker honoraria for Teva Pharmaceutical Industries, Ltd. and ACADIA Pharmaceuticals, Inc.; and has received research support from Teva Pharmaceutical Industries, Ltd. and NINDS. Dr. Ramchandren received research support from the NIH.Dr. Wolfe advises for Grifols, Baxalta, Argenx, and UCB; receives speaker honoraria for Grifols and Baxalta; receives research support from CSL Behring; and serves as Associate Editor for Muscle and Nerve. Dr. Fullard reports no disclosures.

Today in FirstWord:

1) Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up2) What's Trending: Interview with Ben Utecht about his recently published book titled: Counting the Days While My Mind Slips Away: A Love Letter to My Family3) Topic of the month: Neurology Today story about NEJM published paper on thymectomy for patients with myasthenia gravisThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Maarten Titulaer about his paper on the clinical features and long-term follow-up of anti-LGI1 encephalitis. Dr. Ted Burns is interviewing Mr. Ben Utecht for our “What's Trending” feature of the week about his recently published book titled: “Counting the Days While My Mind Slips Away: A Love Letter to My Family.” In the next part of the podcast Dr. Ted Burns interviews Dr. Gil Wolfe about a Neurology Today story on the topic of thymectomy for patients with myasthenia gravis.DISCLOSURES: Dr. Titulaer serves on the scientific advisory board for MedImmune; serves as an editorial board member for Neurology®: Neuroimmunology & Neuroinflammation; received funding for travel from Sun Pharma; receives research support from Netherlands Organization for Scientific Research, Dutch Epilepsy Foundations and ErasmusMC fellowship.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Mr. Ben Utecht receives honoraria from the American Academy of Neurology and the American Brain Foundation, Spokesperson Agreement.Dr. Wolfe serves as an Associate Editor of Muscle and Nerve; serves on the scientific advisory board for Grifols, Baxalta, Argen X and UCB; receives honoraria for serving on the speakers' bureau of Grifols and Baxalta; receives research support from CSL Behring.

Employee experience has emerged as a disruptive force in HR. Social media, cloud, analytics and related technologies now offer HR leaders with a plethora of tools to unlock the potential of employees by engaging with them throughout the entire employee relationship life-cycle. To what extent should the type of design that drives customer experience influence the design and delivery of the employee experience? Kausik Sarkar, VP and Global HR Head – Operations at Baxalta discusses the case for improving employee experience in the digital era.

Today in FirstWord:

Papo de dividendo dessa semana vai falar sobre: – Seagate sofrendo – Canadian Pacific disse que agora acabou – Briga por Yahoo se resume a 2 empresas – Veja as vendas da Nestle e Unilever – McDonalds está vendendo restaurantes, se interessa em comprar ? – Baxalta e Shire – Fiat vai fazer fusão com… […] The post Papo de Dividendo #5: STX – CP – YHOO – NSRGY – UL – MCD – BXLT – FCAU – SAP – DBOEY appeared first on Viver de Dividendos.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Rangeley Capital’s Portfolio Managers, Andrew Walker and Chris DeMuth, discuss the merger of Baxalta and Shire, and how to increase your odds of winning the lottery.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord: